MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Antibody Poses A Double Threat to Breast Cancer

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Antibody Poses A Double Threat to Breast Cancer




A small, antibody-like molecule created by scientists at Fox Chase Cancer Center can successfully attack two separate molecules on the surface of cancer cells at the same time, halting the growth of breast cancer cells in laboratory tests, the scientists say. The molecule, nickname "ALM," might be a means of slowing cancer spread or, as the scientists believe, a guidance system for delivering more aggressive drugs directly to cancer cells. Their findings are published in this month's British Journal of Cancer.



Antibody Poses A Double Threat to Breast Cancer
ErbB2 (blue) combines with ErbB3 (yellow) on the surface of the cancer cell. When a signaling molecule (red) attaches to ErbB3, ErbB2 sends a pro-cancer message within the cell. The ALM antibody forces ErbB2 and ErbB3 apart.
Credit: Fox Chase Cancer Center For a high resolution version

Unlike naturally occurring antibodies, which only bind to one specific target at a time, ALM is bispecific, meaning it attaches to two separate targets simultaneously. ALM's targets are two signaling proteins, ErbB2 and ErbB3, which connect to form a growth-promoting complex on the surface of a number of cancer cells, including head and neck cancer and drug-resistant breast cancer.

"ALM grabs the ErbB2-ErbB3 complex strongly with both hands, as it were, providing a solid grip on the tumor and blocking the transmission of a growth signal within the cell," said lead investigator Matthew Robinson, PhD, an associate member of Fox Chase and a researcher in the Fox Chase Head and Neck Cancer Keystone Program. "Potentially, it can become a platform for delivering therapeutics directly to cancer cells or a way of detecting the presence and location of individual tumors."

ErbB2 and ErbB3 are the protein products of two known cancer-related genes, Her2 and Her3, respectively. In normal cells, the ErbB family of proteins has a role in regulating cell growth and survival. Some malignant cells overproduce copies of ErbB2 and ErbB3, and these excess proteins can bind to each other in a way that generates further cancer-promoting growth signals within a cell. While it is possible that the bound receptor proteins might be found on normal cells, cancer cells possess up to 18 times more of these receptors.

"Because tumors that express the ErbB2-ErbB3 complex are highly aggressive and prone to relapse after initial therapy, this subset of cancer is linked to metastasis and poor patient outcome," Robinson says.

ALM was developed over a number of years at Fox Chase in the laboratory of co-author Greg Adams, PhD, in collaboration with James Marks, MD, PhD, of the University of California, San Francisco, and Louis Weiner, MD, a former Fox Chase senior member and current director of the Lombardi Comprehensive Cancer Center at Georgetown University. The Adams lab created ALM by taking the active anti-ErbB2 portion from one antibody and linking it with the anti-ErbB3 portion from another.

"ALM is a fraction of the size and weight of a naturally occurring antibody and uniquely suited for its task," Robinson says. "In essence, it can get between ErbB2 and ErbB3 and hold them apart at arm's length, much like you would if you were separating two fighting children".

In their experiments, Robinson and colleagues examined the ability of ALM to distinguish cancer cells from normal cells in cell culture and in a mouse model of disease. They observed that ALM preferentially selects tumor cells that express the receptor complex over normal cells that express low levels of both receptors individually.

However, therapy with ALM, by itself, is not really practical, as per Robinson. "As a therapeutic, ALM would need to be taken daily, since it would be rapidly cleared from the body," Robinson says. "While ALM can stop cancer cells from growing and possibly even spreading, it only has a modest ability to kill cancer cells."

In the effort to kill cancer cells, Robinson says, it might be best not to think of ALM as a warrior but as a delivery system. The small amino acid chain that links its two active areas can also serve as a trailer hitch for stronger, more effective cancer-killing drugs.

"Since ALM is so specific for its target - and since its target is only found in great numbers on cancer cells - it could be used to tow what would otherwise be considered toxic therapeutics directly to cancer cells, without harming nearby healthy cells," Robinson says. "We are currently investigating how best to tether other molecules to the antibody in order to target metastatic breast cancer and related diseases".

As per Robinson, ALM might also provide a platform for diagnosing cancer. By conjugating the antibody with a marker molecule, ALM could be used to detect small cancers early or to determine the extent of cancer spread. Robinson and colleagues are currently studying ALM's diagnostic and therapeutic potential.


Posted by: Janet    Source




Did you know?
A small, antibody-like molecule created by scientists at Fox Chase Cancer Center can successfully attack two separate molecules on the surface of cancer cells at the same time, halting the growth of breast cancer cells in laboratory tests, the scientists say. The molecule, nickname "ALM," might be a means of slowing cancer spread or, as the scientists believe, a guidance system for delivering more aggressive drugs directly to cancer cells. Their findings are published in this month's British Journal of Cancer.

Medicineworld.org: Antibody Poses A Double Threat to Breast Cancer

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.